Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients

被引:8
作者
Fu, Chengcheng [1 ]
Wang, Juan [1 ]
Xin, Xue [1 ]
Liu, Hui [1 ]
Xue, Shengli [1 ]
Ma, Xiao [1 ]
Jin, Zhengming [1 ]
Sun, Aining [1 ]
Qiu, Huiying [1 ]
Wu, Depei [1 ]
机构
[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Key Lab Thrombosis & Hemostasis,Minist Hlth, Suzhou 215006, Jiangsu, Peoples R China
关键词
multiple myeloma; autologous hematopoietic stem cell transplantation; prognosis; LONG-TERM SURVIVAL; COMPLETE RESPONSE; THALIDOMIDE; BORTEZOMIB; DEXAMETHASONE; IMPROVEMENT; MELPHALAN; TRIAL; IFM; ARM;
D O I
10.3892/etm.2013.1261
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The present study aimed to evaluate the effect of autologous hematopoietic stem cell transplantation (ASCT) on the response and outcome of patients with multiple myeloma (MM) and to analyze the factors influencing the prognosis of the disease. Retrospective analysis was performed in 27 patients with MM who had been treated by ASCT (ASCT group) and 28 patients treated with combined chemotherapy only (non-ASCT group) from May 2004 to August 2011. The impact on the depth of response, progression-free survival (PFS) and overall survival (OS) times, as well as associated prognostic factors of patients with MM, were analyzed. All patients successfully underwent hematopoietic reconstruction without transplantation-related mortality. The complete remission (CR) rate of patients in the ASCT group significantly increased from 25.9% (7/27) before ASCT to 70.4% (19/27) following ASCT (P<0.01). The probability of OS for 5 years was 52.2% for the patients in the ASCT group and 33.1% for those in the non-ASCT group (P>0.05). Univariate analysis in the ASCT group demonstrated that maintenance and consolidation therapies were associated with significant increases in PFS (P=0.01) and OS (P<0.01) times. The present study demonstrated that ASCT further increases the CR rate, prolongs PFS time and potentially increases the OS time. Incorporation of these novel agents, including the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide, into the induction, consolidation and maintenance phases has optimized the anti-myeloma activity of ASCT.
引用
收藏
页码:977 / 982
页数:6
相关论文
共 23 条
[1]   Multiple Myeloma [J].
Anderson, Kenneth C. ;
Alsina, Melissa ;
Bensinger, William ;
Biermann, J. Sybil ;
Chanan-Khan, Asher ;
Cohen, Adam D. ;
Devine, Steven ;
Djulbegovic, Benjamin ;
Faber, Edward A., Jr. ;
Gasparetto, Cristina ;
Huff, Carol Ann ;
Kassim, Adetola ;
Medeiros, Bruno C. ;
Meredith, Ruby ;
Raje, Noopur ;
Schriber, Jeffrey ;
Singhal, Seema ;
Somlo, George ;
Stockerl-Goldstein, Keith ;
Treon, Steven P. ;
Tricot, Guido ;
Weber, Donna M. ;
Yahalom, Joachim ;
Yunus, Furhan .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (10) :1146-1183
[2]  
[Anonymous], J CLIN ONCOL
[3]  
[Anonymous], J CLIN ONCOL S
[4]   Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma [J].
Attal, Michel ;
Harousseau, Jean-Luc ;
Leyvraz, Serge ;
Doyen, Chantal ;
Hulin, Cyrille ;
Benboubker, Lofti ;
Agha, Ibrahim Yakoub ;
Bourhis, Jean-Henri ;
Garderet, Laurent ;
Pegourie, Brigitte ;
Dumontet, Charles ;
Renaud, Marc ;
Voillat, Laurent ;
Berthou, Christian ;
Marit, Gerald ;
Monconduit, Mathieu ;
Caillot, Denis ;
Grobois, Bernard ;
Avet-Loiseau, Herve ;
Moreau, Philippe ;
Facon, Thierry .
BLOOD, 2006, 108 (10) :3289-3294
[5]   Thalidomide and hematopoietic-cell transplantation for multiple myeloma [J].
Barlogie, B ;
Tricot, G ;
Anaissie, E ;
Shaughnessy, J ;
Rasmussen, E ;
van Rhee, F ;
Fassas, A ;
Zangari, M ;
Hollmig, K ;
Pineda-Roman, M ;
Lee, C ;
Talamo, G ;
Thertulien, R ;
Kiwan, E ;
Krishna, S ;
Fox, M ;
Crowley, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1021-1030
[6]   Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities [J].
Barlogie, Bart ;
Pineda-Roman, Mauricio ;
Van Rhee, Frits ;
Haessler, Jeff ;
Anaissie, Elias ;
Hollmig, Klaus ;
Alsayed, Yazan ;
Waheed, Sarah ;
Petty, Nathan ;
Epstein, Joshua ;
Shaughnessy, John D., Jr. ;
Tricot, Guido ;
Zangari, Maurizio ;
Zeldis, Jerome ;
Barer, Sol ;
Crowley, John .
BLOOD, 2008, 112 (08) :3115-3121
[7]   Hematopoietic stem cell transplantation for multiple myeloma beyond 2010 [J].
Blade, Joan ;
Rosinol, Laura ;
Cibeira, Maria Teresa ;
Rovira, Montserrat ;
Carreras, Enric .
BLOOD, 2010, 115 (18) :3655-3663
[8]   Recent major improvement in long-term survival of younger patients with multiple myeloma [J].
Brenner, Hermann ;
Gondos, Adam ;
Pulte, Dianne .
BLOOD, 2008, 111 (05) :2521-2526
[9]   Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma [J].
Cavo, M ;
Zamagni, E ;
Tosi, P ;
Tacchetti, P ;
Cellini, C ;
Cangini, D ;
de Vivo, A ;
Testoni, N ;
Nicci, C ;
Terragna, C ;
Grafone, T ;
Perrone, G ;
Ceccolini, M ;
Tura, S ;
Baccarani, M .
BLOOD, 2005, 106 (01) :35-39
[10]  
Harousseau JL, 2007, BLOOD, V110, p1052A